deficiencies, and those residing in crowded living conditions such as in college dormitories. The incidence of invasive meningococcal disease varies geographically with some countries (e.g., in the African meningitis belt) having both high endemic disease rates and ongoing epidemics, with annual rates reaching 1000 cases per 100,000 persons. Given the significant morbidity and 
MENINGOCOCCAL DISEASE
Meningococcal disease is caused by the gram-negative diplococcus, Neisseria meningitidis. Although clinical descriptions of the disease occurred in the early 1880s [1] , the first description of the organism in cerebrospinal fluid (CSF) is attributed to Marchiafava and Celli [2] . Three years later, Weichselbaum identified and cultured the organism [3] . The meningococcus, which only infects humans, may colonize the mucosal surfaces of the nasopharynx and upper respiratory tract.
Colonization occurs in approximately 10%
(range 3-25%) of the population with the highest rates among adolescents and closed populations (college students, military recruits and multi-person households) [4] . Colonization may last days (transient) or months (persistent), the latter of which may serve as an immunizing event providing protection against future invasive infection [5] [6] [7] . Acquisition of the bacteria from a carrier or infected person occurs through direct contact with large-droplet respiratory secretions, including activities such as kissing, coughing and sharing eating/drinking utensils. Meningococcal disease develops after the bacteria invades across the mucosal surface and enters the bloodstream. Onset is typically rapid, and fulminant disease may develop 1-14 days after acquisition [8, 9] . Clinical syndromes include meningitis with or without meningococcemia, the latter often manifesting with a petechial rash or purpura fulminans [1] .
N. meningitidis remains the first or second most common cause of meningitis in many geographic areas including the US and is the only bacterium with the ability to produce large meningitis outbreaks [10] [11] [12] . Other clinical presentations of N. meningitidis infection include pneumonia, arthritis, myocarditis, pericarditis, urethritis and endophthalmitis [1, 9, 13, 14] . Infections frequently occur among previously healthy persons often with resultant high morbidity and mortality. In the developed world, the mortality rate remains 10-15%, with rates of C20% in developing countries [1] . Among survivors, up to 19% have long-term sequelae including neurologic disabilities, seizures, hearing or visual loss, cognitive impairment, and loss of digits or limbs [8, 9, 15, 16] . Given the ability of the meningococcus to cause rapidly fatal and epidemic disease worldwide, understanding preventive strategies against this pathogen represents a global health priority for healthcare providers, public health personnel, and government officials worldwide. [25] . Serogroup B predominates in Australia and New Zealand with a notable reduction in serogroup C post introduction of meningococcal C conjugate vaccine in Australia, whereas the incidence of serogroup C has remained unchanged in New
Zealand with approximately 10-30 cases per year during the past 10 years [22] . Serogroups A, B and C predominate in Russia; and based on limited data, serogroups A and C in Asia with serogroup B responsible for sporadic cases in China [17, 23] . Serogroups B and Y cause the majority of meningococcal disease cases in Japan, even though the incidence is very low with an estimated \30 cases per year [17] . In South and Latin America, B and C are most deaths [23] . While the incidence in Africa varies over time and by geographic location, annual rates up to 1000 cases per 100,000 population (which is 1 case per 100 persons) have been described [14, 22] . In Europe, the incidence is estimated as 0.92 cases per 100,000 population, while in the Americas rates range from 0.3 to 4 cases per 100,000 population [14, 22] . An estimated 600-1200 cases occur in the US annually with a current rate of 0.18 cases per 100,000 population [34, 35] .
RISK FACTORS FOR INVASIVE DISEASE
Since less than 1-5% of persons exposed to the organism develop invasive disease [1] , it is known that characteristics of the organism, host, and environment likely play a role in disease pathogenesis. Regarding the organism, capsular strains of N. meningitidis are more likely to cause invasive disease as the polysaccharide capsule serves as an important virulence factor allowing for evasion of opsonization as well as complement and phagocytic-mediated killing [36] . Further, specific genotypes of encapsulated organisms, designated as ST clonal complexes, vary in their virulence as shown by case:carrier ratio studies [7, 37] . For example, serogroup W (cc11) has been associated with both severe and unusual presentations of the disease [25, 29] .
Host factors that result in the absence of protective bactericidal activity (due to a deficiency in complement or antibody production) are also risk factors for invasive meningococcal disease. These include functional or anatomic asplenia as well as persistent complement deficiencies (i.e., C3, C5-9, properdin, factor D and factor H) [38, 39] . For example, terminal complement deficiencies (C5-9) are associated with a 1400-to 10,000-fold increase in meningococcal disease as well as the propensity for recurrent infections (in up to 50% of patients) [1, 38] .
Conditions with reduced complement levels such as systemic lupus erythematous (e.g., low C3 levels) also increase the risk. Similarly, medications that inhibit relevant host immune responses (e.g., eculizumab, a humanized monoclonal antibody that inhibits terminal complement) are risk factors [40] .
Conditions associated with poor antibody responses (e.g., congenital or acquired antibody deficiencies such as seen in hypogammaglobulinemia and glomerulonephritis) also pose a risk for invasive disease [5, 6, 41] , and among these groups, atypical presentations of invasive disease have been described [41] . Whether HIV-infection is a risk factor has been debated; however, studies have shown those with AIDS or low CD4 counts are at higher risk compared with the general population [42] . Additionally, outbreaks have been described among HIV-infected men who have sex with men (MSM) engaging in high-risk sexual behaviors [43] .
Finally, specific host genetic polymorphisms have also been associated with invasive disease [44] [45] [46] to be at higher risk unless exposed to a patient with meningococcal disease [49] . Other environmental risks include residence or travel to hyperendemic areas (e.g., the meningitis belt in Africa) as well as pilgrimages to the Hajj in Mecca [51, 52] . Finally, antecedent respiratory infections (e.g., Mycoplasma, influenza and other viruses), exposure to active or passive smoking, and dry or windy air conditions are associated with a heightened risk for invasive disease due to mucosal damage and/or irritation [53] [54] [55] .
An example of the culmination of multiple risk factors that previously led to extremely high incidence rates was seen in the African meningitis belt, stretching from Senegal in the west to Ethiopia in the east. During the dry season (December-June), dusty winds, cold nights and upper respiratory tract infections combined to damage the nasopharyngeal mucosa [55, 56] . Additionally, overcrowding, exposures during migration and congregating at traditional markets, and underlying medical conditions enhanced the risk for disease. The combination of these factors and the presence of encapsulated, virulent serogroups of N. meningitidis explained the previous enormous burden of meningococcal disease observed in these areas prior to the institution of massive vaccination campaigns.
MENINGOCOCCAL VACCINATIONS

Overview
While N. meningitidis remains a formidable pathogen, tremendous strides toward its control have been made, including the development of effective vaccines, which first became available [40 years ago [57, 58] .
Advances in the immunogenicity and breadth of serogroup coverage of the vaccines have readily expanded over time [59] .
Available Vaccines
Both polysaccharide and conjugated polysaccharide meningococcal vaccines are currently available (Table 1) No vaccine currently exists against serogroup X; however, candidate glycoconjugate vaccines are in development against this serogroup [60] .
The development of an effective vaccine against serogroup B has been challenging, especially given the serogroup B polysaccharide resembles a human neural cell adhesion molecule, raising concern about autoimmunity [61] . Initially serogroup B vaccines were developed based on outer membrane vesicles (OMV) that contain proteins. OMV vaccines have been utilized in many areas (e.g., Cuba, South America, Norway and New Zealand) with demonstrated protective capacities against serogroup B. For example, the MeNZBÒ, utilized in New Zealand, was effective in reducing rates of disease and controlling a serogroup B epidemic [62] . The main limitation of these vaccines is their lack of broad protection against the wide global diversity of varying serogroup B strains.
Hence, improved vaccines against serogroup B were pursued with the subsequent recent breakthroughs using ''reverse vaccinology,'' which successfully created serogroup B meningococcal vaccines based on conserved proteins [63, 64] . The advantages of these new serogroup B vaccines are several fold, including their broad coverage, which may protect even given as a two-dose (0 and C1 month) and MenB-FHbp as a three-dose (0, 2 and 6 months) initial series; the same serogroup B vaccine should be utilized for all doses. Quadrivalent and serogroup B vaccines can be administered during the same visit, but should be given at different sites.
Vaccine Recommendations
Meningococcal vaccination is recommended for persons at increased risk for disease. A summary of vaccine recommendations is shown in 
years 4vMenCV
Entering university with an unknown immunization history 
Guidelines for Lower-Risk Countries
Meningococcal vaccination decisions in areas of low incidence (\2 cases per 100,000) are more challenging. While low incidence rates of disease are typically seen in the developed world, invasive disease does occur and is often associated with high mortality rates and substantial disability among survivors [15, 16, 49] . Guidelines regarding meningococcal vaccination in countries with overall low disease rates and without frequent epidemics is variable, but most (e.g., US, Europe) recommend vaccination for defined ''at-risk'' groups based on age, underlying host factors, and anticipated occupational and or travel-related exposures.
US Guidelines
In the US, meningococcal vaccination is guided by the Advisory Committee on Immunization Practices (ACIP) with available vaccines shown in [49] . US guidelines do not include HIV infection as an indication for vaccination [65] , although specific states (e.g., New York) have encouraged its use in this population.
Finally, vaccine administration should be considered in outbreak settings and directed against the causative serogroup.
Travelers visiting areas with high endemic rates or ongoing epidemics should be vaccinated with a dose received at least within the 5 years prior to travel [65] . For travelers to the African meningitis belt, the risk is highest during the dry season and with anticipated contact with the local population [14] .
Vaccination is required within the last 3 years for travelers to the Hajj (given outbreaks of A, C and W disease), a requirement of the government of Saudi Arabia [76, 77] . Vaccines should be directed against the serogroups that are prevalent in the visited areas and should be given at least 10 days prior to departure to ensure protective antibody levels. [64] . Serogroup B vaccination can also be considered among other at-risk groups (e.g., adolescents, college students); however, it is not currently uniformly recommended given the overall low burden of disease. For example, if the vaccine were administered in the US at ages 11 and 16-18 years, an estimated 15-29 cases and 2-5 deaths might be prevented each year; if given only to college students, an estimated nine cases and one death might be averted each year [80] . If the serogroup B vaccine is utilized, the preferred strategy per ACIP guidelines is to administer it later in adolescence (i.e., aged 16-18 years) to maximize protection during the highest age risk period [80] . Overall, individual clinical decision making has been advised regarding the use of the serogroup B vaccine among US adolescents and young adults who do not have additional risk factors.
Additionally, in the setting of increased serogroup B cases or outbreaks (defined as C2 primary cases in organizations with \5000 persons over a 6 month period), vaccination is advised [64, 65, 81] .
European Guidelines
The use of meningococcal vaccination in Europe differs from the US given the geographically varying epidemiologic trends. In 1999, the MenC conjugate vaccine was added to the UK's routine immunization schedule, resulting in significant and sustained reductions in serogroup C cases [22, 68] . In 2013, the serogroup B vaccine, MenB-4C, was approved for persons C2 months of age and subsequently added to the vaccine schedule [82] . Current UK guidelines suggest the administration of two doses of serogroup B at 2 and 4 months followed by a booster at Hence, a quadrivalent meningococcal conjugate (ACWY-CRM or ACWY-TT) is administered among these age groups. For those entering university with an unknown immunization history, a conjugate quadrivalent ACWY vaccine dose is also recommended ( Table 2 ).
In addition, those at risk for disease (e.g., asplenia, complement disorders) should receive vaccination based on the age at which their risk condition is diagnosed [68] . The UK guidelines also recommend a dose of conjugate MenACWY for those traveling to hyperendemic or epidemic areas, even if previously vaccinated with MenC [68] . Finally, the British HIV Association suggests vaccination among HIV-infected persons aged \25 years [69] .
Other European countries have also introduced meningococcal C vaccinations into their immunization programs, some as part of the infant immunization schedule (e.g., Greece, Iceland, Ireland, Portugal, Spain and the UK), while others advise initiation during the 2nd year of life (e.g., Belgium, Cyprus, Italy and The Netherlands) [22, 85] . The European Commission approved MenB-4C in 2013, and the UK subsequently was the first country to introduce MenB-4C into their national infant immunization program (2015). As noted above, most countries also recommend vaccination among those at high risk for disease (e.g., asplenia, terminal complement deficiencies) and travelers to endemic areas with some variations by country. A summary of European recommendations by country can be found on the European Centre for Disease Prevention and Control website [85] .
Guidelines for Other Locations
Country-specific guidelines have been developed for other regions of the world [22, 87] . Guidance for Australia and Canada are shown in Table 2 
Number of Vaccinations
Establishment of protection against invasive disease is via the development of serum bactericidal antibodies against N. meningitidis capsular polysaccharides or protein antigens.
Due to the low incidence of meningococcal disease in much of the world, vaccine effectiveness has largely been based on immunogenicity data as measured by serum bactericidal activity (SBA) [14] .
The number of vaccines utilized in the initial series is based on host characteristics including age and underlying medical conditions. In most adults and children (age C24 months), a single dose is recommended for initial vaccination.
Additional doses are generally recommended among infants and toddlers B23 months [68, 89] . Furthermore, among children and adults with underlying medical conditions [e.g., asplenia, persistent complement component deficiencies and immunosuppression (e.g., HIV)], significantly lower antibody titers have been achieved after a single dose [90, 91] .
Hence, when these groups are vaccinated, additional vaccine doses are often recommended [65] [66] [67] [68] [69] [70] . For example, in the US, these groups receive a two-dose initial series administered 8-12 weeks apart [49, 65] . [65] [66] [67] [68] [69] [70] . Among children at higher risk for disease, revaccination is recommended 3 years after the initial dose if received at an age B6 years [49, 92] .
Vaccine Administration
Most polysaccharide vaccines are administered by subcutaneous injection, whereas conjugate vaccines are given by intramuscular injection, typically in the deltoid muscle, except among those \12 months, in whom the anterolateral thigh is preferred [14] .
Co [98, 99] . Allergic reactions and/or anaphylaxis are uncommon (e.g., estimated as \0.1/100,000 vaccines doses for polysaccharide vaccines) [14] .
Use in Pregnancy
Although meningococcal vaccines have not been extensively studied in pregnancy or lactating women and no randomized trials are available, an observational study of the MenAfriVac did not show any adverse signals for pregnancy outcomes. As such, pregnant women in the targeted age range are being included in the mass vaccine campaigns in Africa [74] . Similarly, the Vaccine Adverse Event Reporting System (VAERS) system in the US has identified no major safety concerns in the mother or fetus [49, 100] . Hence, based on the available data, pregnancy or lactation is not considered as an exclusion for vaccination [74, 101] .
OTHER PREVENTION STRATEGIES INCLUDING ANTIBIOTIC PROPHYLAXIS
Close contacts of patients with invasive disease have a markedly increased risk for developing meningococcal infection (estimated as [100-fold increase compared with the general population) [49, 102] . As such, prophylactic antibiotics are recommended for close contacts including household members or persons in the same daycare, college dormitory or military unit [49, 92] . Additionally, those directly exposed to a patient's oral secretions (kissing, sharing food or drink utensils, or mouth-to-mouth resuscitation) within the 7 days before symptom onset should be offered prophylaxis [49] .
Secondary cases most often occur within 72 h of presentation of the index cases; hence, antibiotic prophylaxis should be initiated immediately, ideally within 24 h of the identification of the index case. Presentation may occur up to 14 days of exposure; hence, prophylaxis can be offered up to this time point [49] . Chemoprophylaxis in the setting of ongoing epidemics and exposures (e.g., the African meningitis belt) are often not pursued given the multiple sources and prolonged risk of exposures; vaccine protection is the best preventive strategy in these settings.
Prophylactic antibiotic regimens may include oral ciprofloxacin (adult dose: 500 mg 9 1 dose), ceftriaxone (adult dose: 250 mg IM 9 1; children \15 years: 125 mg IM 9 1), rifampin (dose dependent on age; adult dose: 600 mg po bid 9 2 days) or azithromycin (10 mg/kg with maximum dose of 500 mg 9 1) [49, 103] . Effectiveness is estimated as 90-95% [104] . The preferred chemoprophylaxis depends on existing resistance patterns among strains in the geographic area of acquisition as well as host characteristics such as age, underlying medical conditions, pregnancy status and concurrent medications. For example, reports of rifampin-and ciprofloxacin-resistant N. meningitidis isolates have been described [105, 106] .
Other methods for preventing disease include prompt diagnosis and management of patients with invasive disease. Historically, treatment was with immune antiserum and then with sulfonamides during the early antibiotic era [1, 107] 
